Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491699 | 0.86 | HTR2C (0.39) | SMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL6493979 | 0.82 | HTR2C (0.36) | PIK3CAHTR2AHTR2CHTR2B | |
| SCHEMBL6784256 | 0.82 | HTR2C (0.37) | KDM4ESMN1; SMN2HSD17B10HTR2AHTR2C | |
| SCHEMBL6499854 | 0.81 | CHEK1 (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL6783539 | 0.81 | HTR2C (0.39) | PIK3CAHTR2AHTR2CHTR2B | |
| SCHEMBL6490790 | 0.81 | HTR2C (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL6783840 | 0.80 | HTR2C (0.43) | SMN1; SMN2PIK3CAHTR2AHTR2CHTR2B | |
| SCHEMBL6501176 | 0.79 | HTR2C (0.34) | HTR2AHTR2CHTR2B | |
| SCHEMBL6493032 | 0.79 | HTR2C (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL6789705 | 0.79 | HTR2C (0.35) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | claimed |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-6699852-B2 | ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173503-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | KDM4E 2300/4885NPC1 1661/4885SMN1; SMN2 1973/4885 |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | KDM4E 2300/4885NPC1 1661/4885SMN1; SMN2 1973/4885 |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | KDM4E 1071/4885NPC1 45/4885SMN1; SMN2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.